EUVIMEDEUVIMED entdecken
Crossref

Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma

Takaaki Furukawa, Ippei Fukada, Naomi Hayashi, Takeshi Okamoto, Yoichiro Sato, Yuri Maegawa, Tatsuki Hirai, Takafumi Mie, Tsuyoshi Takeda, Takashi Sasaki, Masato Ozaka, Shunji Takahashi und 1 weitere

Pancreatology · 2025

DOI: 10.1016/j.pan.2025.06.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2025. Verfasst von Takaaki Furukawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of G…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Liquid biopsy offers an alternative to tissue specimens for comprehensive genomic profiling. However, detection of circulating tumor DNA (ctDNA) remains challenging in pancreatic ductal adenocarcinoma (PDAC). This study assessed predictive ability of CA19-9 and other factors for detecting KRAS mutations on liquid biopsy. METHODS: We retrospectively reviewed clinical and genomic databases for PDAC patients who underwent liquid biopsy between September 2021 and August 2024. RESULTS: A total of 106 patients were enrolled. The overall detection rate of KRAS mutations was 48 %. Univariate analysis identified hepatic metastases (Odds ratio (OR) 4.50, p 10 % compared to those with Max VAF

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Carcinoma, Pancreatic DuctalPancreatic NeoplasmsMutationHumansMaleFemaleAgedMiddle AgedLiquid BiopsyRetrospective StudiesAged, 80 and overAdultCA-19-9 AntigenPrognosisCirculating Tumor DNA

Stichwörter der Autor:innen

CA19-9Hepatic metastasesKRAS mutationsLiquid biopsyPancreatic ductal adenocarcinoma

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanCA-19-9 AntigenCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for…
  • Department of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Zitieren

APA

Furukawa, T., Fukada, I., Hayashi, N., Okamoto, T., Sato, Y., Maegawa, Y., Hirai, T., Mie, T., Takeda, T., Sasaki, T., Ozaka, M., Takahashi, S., & Sasahira, N. (2025). Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Pancreatology. https://doi.org/10.1016/j.pan.2025.06.013

Vancouver

Furukawa T, Fukada I, Hayashi N, Okamoto T, Sato Y, Maegawa Y, et al. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Pancreatology. 2025. doi:10.1016/j.pan.2025.06.013

BibTeX
@article{Furukawa2025,
  author = {Furukawa, Takaaki and Fukada, Ippei and Hayashi, Naomi and Okamoto, Takeshi and Sato, Yoichiro and Maegawa, Yuri and Hirai, Tatsuki and Mie, Takafumi and Takeda, Tsuyoshi and Sasaki, Takashi and Ozaka, Masato and Takahashi, Shunji and Sasahira, Naoki},
  title = {Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma},
  journal = {Pancreatology},
  year = {2025},
  doi = {10.1016/j.pan.2025.06.013}
}
Kostenlos starten →